Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Evaluation of Treatment Satisfaction and Preference for Sumavel DosePro in the Treatment of Migraine

NCT: NCT01016834 · COMPLETED

NCT IDNCT01016834
StatusCOMPLETED
Start Date2009-11-30
Completion2010-04-30
SponsorZogenix, Inc. (INDUSTRY)
First posted
Last updated

Brief Summary

The purpose of the study is to evaluate the treatment satisfaction of subjects using Sumavel DosePro to treat their moderate to severe migraines.

Frequently Asked Questions

What is Evaluation of Treatment Satisfaction and Preference for Sumavel DosePro in the Treatment of Migraine?

Evaluation of Treatment Satisfaction and Preference for Sumavel DosePro in the Treatment of Migraine is a clinical trial registered under NCT01016834. Current status: COMPLETED.

What is the status of NCT01016834?

The current status of NCT01016834 (Evaluation of Treatment Satisfaction and Preference for Sumavel DosePro in the Treatment of Migraine) is: COMPLETED.

When did Evaluation of Treatment Satisfaction and Preference for Sumavel DosePro in the Treatment of Migraine start?

Evaluation of Treatment Satisfaction and Preference for Sumavel DosePro in the Treatment of Migraine started on 2009-11-30.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑